| abstract |
The present invention relates to a novel physiological substrate of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), a new effector of QC, a screening method for such an effector, and modulation of QC activity. There is provided such an effector and a pharmaceutical composition comprising such an effector for the treatment of a condition treatable by. In addition, preferred compositions include inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of pathologies treatable by modulation of QC and DP IV activity. |